Venture Capital Access Online | Venture Capital News
Summary
McKinsey estimates that over 60% of inputs to the global economy can be biologically produced, representing the potential for $2 to $4 trillion per year of direct economic impact over the next two decades across pharmaceuticals, agriculture, food, industrial fuels and materials, and consumer packaged goods. Modern R&D holds the key to unleashing biotechnologys potential to radically transform our world scientists must be empowered to discover and develop the next generation of medicines and biologically derived products, and ultimately get them to market faster than ever before. Our customers, spanning nearly every major industry, are engineering more effective medicines, nutritious foods, and sustainable crops, materials, and fuels to address humanitys most pressing challenges," said Sajith Wickramasekara, CEO and co-founder of Benchling. Benchlings unified R&D platform allows us to capture, standardize, and share data so we can learn from past experiments and make smarter decisions faster," said Frantz Gabeau, Senior Research Scientist at Gilead. In just one year since entering the EMEA market, Benchling has reached over 90 customers in Europe, including Cutiss AG, Sanofi, Selexis SA, and Syngenta, and grown its European team to over 60 people.